UNSPSC 51333703: Belaperidone

This classification denotes an antipsychotic agent with the molecular formula C22H22FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4DN0TK4892, chemically known as 2,4(1h,3h)-quinazolinedione, 3-(2-((1s,5r,6s)-6-(4-fluorophenyl)-3-azabicyclo(3.2.0)hept-3-yl)ethyl)- but generally known as belaperidone, which bears US NIH Compound Identifier 184841. European Medicines Agency schedules Belaperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05685MIG.

UNSPSC 51333703 Belaperidone, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The code nominally names a single antipsychotic pharmaceutical, but the recent opportunities posted under this code span naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products — none of which are belaperidone or closely related to it. The mismatch suggests either a data-tagging error in the procurement system or a misalignment between the code's intended scope and how jurisdictions are categorizing pharmaceutical acquisitions in practice.

Recent activity shows three distinct opportunities across different issuing bodies and procurement models. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually for its community health initiatives, with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities for a Therapeutic Pharmacy Initiative focused on self-insured employers and state agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) across participating state and local facilities in Minnesota and Oregon, with pricing weighted 75 percent in the evaluation. The code shows activity across state agencies, county health departments, and cooperative purchasing vehicles, but the pharmaceutical scope is too broad and heterogeneous — and misaligned with belaperidone specifically — to warrant pursuit under this code designation.